Our Chief Executive, Chris Molloy, provided an exclusive comment to Pharmafield:
“The NHS 10 year plan puts the patient at the heart. We need to understand diseases at a granular level and diagnose and treat at that level as well as at an earlier stage. It’s really important to have the right targeted therapeutics to meet the needs.
At Medicines Discovery Catapult, we work with industry to understand how data and diagnostics can better characterise diseases and help the industry to produce therapeutics to match those disease subsets and meet the needs of the patients.
As with the recent second Life Science Industrial Strategy, it’s essential to access the capability of the NHS for medicines discovery. If we can make each hospital a research hospital, involve each patient in research if they agree, the UK has an immense opportunity to lead the world in medicines R&D.”
Read the full Pharmafield article